GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

voxelotor   Click here for help

GtoPdb Ligand ID: 10559

Synonyms: compound 36 [PMID: 28337324] | GBT-440 | GBT440 | Oxbryta®
Approved drug
voxelotor is an approved drug (FDA (2019), EMA (2022))
Compound class: Synthetic organic
Comment: Voxelotor (GBT440) is an orally bioavailable drug that acts allosterically to stabilise the relaxed (R)-state of sickle cell haemoglobin (HbS) in which it has high affinity for oxygen, and this mechanism reduces the HbS polymerisation that drives erythrocyte sickling [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

voxelotor is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 77.24
Molecular weight 337.14
XLogP 3.61
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES O=Cc1c(cccc1O)OCc1cccnc1c1ccnn1C(C)C
Isomeric SMILES O=Cc1c(cccc1O)OCc1cccnc1c1ccnn1C(C)C
InChI InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3
InChI Key FWCVZAQENIZVMY-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Phase 3 clinical trial results were published by Vichinsky et al. in August 2019 [2]. Voxelotor was granted FDA accelerated approval in November 2019, for the treatment of sickle cell disease in patients ≥12 years of age. In the EU, the EMA designated voxelotor as an orphan medicinal product for sickle cell disease in November 2016. In late 2024 Pfizer withdrew Oxbryta from all approved markets and discontinued active clinical trials, as the company decided that the number of vaso-occlusive crises and fatal events in patients taking Oxbryta required further investigation [3].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Voxelotor increases HbS' affinity for oxygen and acts to prevent HbS polymerisation and the resultant sickling and destruction of erythrocytes.